Corporate ActionMay 19, 2026, 01:21 PM
BIOFORCE NANOSCIENCES Q1 Net Loss $(102K); Controlling Stake Sold
AI Summary
BIOFORCE NANOSCIENCES HOLDINGS, INC. reported a net loss of $(102,411) for the three months ended March 31, 2026, a substantial improvement from a net loss of $(935,457) in the prior year period, partly due to a $15,322 legal settlement. Despite the improved financial performance, the company continues to face recurring losses and has a going concern issue with zero sales. In a significant corporate action, director Merle Ferguson sold his controlling 80% stock interest to Nexus Capital Investments, Inc. and forgave all his accrued compensation and other amounts due.
Key Highlights
- Net loss for Q1 2026 was $(102,411), a significant improvement from $(935,457) in Q1 2025.
- Merle Ferguson, a director, sold his approximately 80% controlling stock interest to Nexus Capital Investments, Inc. in April 2026.
- Mr. Ferguson cancelled his month-to-month contract and forgave all accrued compensation and other amounts due to him.
- The company received $15,322 in other income from a legal settlement during Q1 2026.
- Cash balance at March 31, 2026, was $6,347, up from $786 at December 31, 2025.
- Total liabilities were $727,301, and accumulated deficit was $(162,514,528) at March 31, 2026.
- Nauri Dean Ahmad converted a $10,000 loan into 24,250 restricted common shares in April 2026.
- The company continues to report recurring losses and has a going concern issue due to insufficient revenues.
Price Impact
More from BFNH